Literature DB >> 16496234

Primary sclerosing cholangitis: the role of endoscopic therapy.

Adolf Stiehl1.   

Abstract

Primary sclerosing cholangitis is characterized by progressive fibrosing inflammation of the bile ducts leading to their obliteration, resulting in cholestasis, and finally, cirrhosis of the liver. The majority of patients with advanced disease with time develop dominant stenoses of major bile ducts. Such dominant stenoses may be recognized by magnetic resonance cholangiopancreatography with good specificity and sensitivity, but for definite diagnosis and especially for therapeutic decisions, endoscopic retrograde cholangiography still represents the gold standard. Ursodeoxycholic acid treatment does not prevent the development of such stenoses. Endoscopic measures allow the opening of short- and long-segment stenoses of the common bile duct. Short- but not long-segment stenoses of the hepatic ducts near to the bifurcation also may be treated endoscopically. Repeated balloon dilatations over years appear to be the treatment of choice. In patients treated by early endoscopic dilatation of dominant stenoses, survival may be significantly improved compared with the predicted survival.

Entities:  

Mesh:

Year:  2006        PMID: 16496234     DOI: 10.1055/s-2006-933564

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  11 in total

1.  What is the current role of endoscopy in primary sclerosing cholangitis?

Authors:  Benjamin Tharian; Nayana Elizabeth George; Tony Chiew Keong Tham
Journal:  World J Gastrointest Endosc       Date:  2015-08-10

Review 2.  Analytical review of diagnosis and treatment strategies for dominant bile duct strictures in patients with primary sclerosing cholangitis.

Authors:  Murad Aljiffry; Paul D Renfrew; Mark J Walsh; Marie Laryea; Michele Molinari
Journal:  HPB (Oxford)       Date:  2011-02       Impact factor: 3.647

Review 3.  The current diagnosis and treatment of benign biliary stricture.

Authors:  Hiroshi Shimada; Itaru Endo; Kazuhiro Shimada; Ryusei Matsuyama; Noritoshi Kobayashi; Kensuke Kubota
Journal:  Surg Today       Date:  2012-09-22       Impact factor: 2.549

4.  In PSC with colitis treated with UDCA, most colonic carcinomas develop in the first years after the start of treatment.

Authors:  G Rudolph; D N Gotthardt; P Kloeters-Plachky; H Kulaksiz; P Schirmacher; A Stiehl
Journal:  Dig Dis Sci       Date:  2011-06-09       Impact factor: 3.199

5.  ACG Clinical Guideline: Primary Sclerosing Cholangitis.

Authors:  Keith D Lindor; Kris V Kowdley; M Edwyn Harrison
Journal:  Am J Gastroenterol       Date:  2015-04-14       Impact factor: 10.864

6.  A comparison of balloon- versus stent-based approach for dominant strictures in primary sclerosing cholangitis: a meta-analysis.

Authors:  Amaninder S Dhaliwal; Yassin Naga; Daryl Ramai; Syed M Saghir; Sarav G Daid; Banreet Dhindsa; Andrew Ofosu; Pushpak Taunk
Journal:  Ann Gastroenterol       Date:  2022-03-25

Review 7.  Endoscopic and surgical management of primary sclerosing cholangitis.

Authors:  Anthony Michaels; Cynthia Levy
Journal:  Medscape J Med       Date:  2008-10-21

Review 8.  The neglected biliary mucus and its phosphatidylcholine content: a putative player in pathogenesis of primary cholangitis-a narrative review article.

Authors:  Wolfgang Stremmel; Martina Lukasova; Ralf Weiskirchen
Journal:  Ann Transl Med       Date:  2021-04

9.  Preventative care in cholestatic liver disease: Pearls for the specialist and subspecialist.

Authors:  Adnan Malik; Ani A Kardashian; Kais Zakharia; Christopher L Bowlus; James H Tabibian
Journal:  Liver Res       Date:  2019-05-27

10.  Clinical guidelines for primary sclerosing cholangitis 2017.

Authors:  Hiroyuki Isayama; Susumu Tazuma; Norihiro Kokudo; Atsushi Tanaka; Toshio Tsuyuguchi; Takahiro Nakazawa; Kenji Notohara; Suguru Mizuno; Nobuhisa Akamatsu; Masahiro Serikawa; Itaru Naitoh; Yoshiki Hirooka; Toshifumi Wakai; Takao Itoi; Tomoki Ebata; Shinji Okaniwa; Terumi Kamisawa; Hiroki Kawashima; Atsushi Kanno; Keiichi Kubota; Masami Tabata; Michiaki Unno; Hajime Takikawa
Journal:  J Gastroenterol       Date:  2018-06-27       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.